ATAGI recommends third booster shot for immunocompromised individuals

ATAGI recommends third booster shot for immunocompromised individuals

Australia’s advisory group on immunisations has today recommended individuals who are “severely immunocompromised” receive a third booster shot of a COVID-19 vaccine two to six months after receiving the second.

The updated advice from the Australian Technical Advisory Group on Immunisation (ATAGI) was provided to address the risk of suboptimal or non-response to the standard two-dose schedule, and is intended to maximise the level of immune response to as close as possible to the general population.

As for which vaccine immunocompromised people should receive, ATAGI recommends an mRNA vaccine (Pfizer or Moderna) over AstraZeneca for the third dose.

However, ATAGI says “AstraZeneca can be used for the third dose for individuals who have received AstraZeneca for their first two doses if there are no contraindications or precautions for use, or if a significant adverse reaction has occurred after a previous mRNA vaccine dose which contraindicates further doses of mRNA vaccine”.

“The recommended interval for the third dose is two to six months after the second dose of vaccine,” says ATAGI.

“A minimum interval of four weeks may be considered in exceptional circumstances (e.g., anticipated intensification of immunosuppression, outbreaks). People who have had a second dose more than 6 months ago should receive a third dose whenever feasible.”

The vaccine advisory group does not recommend subsequent doses beyond the third at this point in time, but notes protection from three doses in severely immunocompromised individuals may still be lower than the general population.

As such, ATAGI recommends people continue risk mitigation strategies such as mask wearing and social distancing even after receipt of a third jab.

“ATAGI will continue to monitor the evidence around duration of protection and advise on the need for subsequent (booster) doses in immunocompromised populations to address waning of protection or risk from variants of concern,” says ATAGI.

“ATAGI will provide further advice on booster doses (including for healthcare workers, older adults and the general population) separately.”

Updated at 2.14pm AEST on 8 October 2021.

This update is brought to you by Employment Hero.

Click here to go to Employment Hero’s COVID-19 Resource Hub for essential resources to help employers, managers and HR specialists navigate the ongoing pandemic. 


 

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How communications technology can raise the bar on customer service, employee experience
Partner Content
From capturing feedback early to providing messages with a higher rate of cut-through, ...
Advertisement

Related Stories

EML Payments awarded $320m government contract to help stimulate the Spanish arts sector

EML Payments awarded $320m government contract to help stimulate the Spanish arts sector

Global payment solutions business EML Payments (ASX: EML) will play...

Microbio goes public as med-tech tackles condition that causes 11 million deaths per year

Microbio goes public as med-tech tackles condition that causes 11 million deaths per year

Brisbane-based medical technology company Microbio has stepped...

Available anywhere and everywhere: Lifestyle brand The Somewhere Co. targets global expansion

Available anywhere and everywhere: Lifestyle brand The Somewhere Co. targets global expansion

Despite a difficult few months for everyday wares outfit The Somewh...

G'day space: Australia is "go" for launch

G'day space: Australia is "go" for launch

Just after midnight on Monday 27 June, above the vast wilderness of...